Update in Immuno-Oncology: Multiplicity of Drug In-Licensing Opportunities to Expand Your Pipeline

Update in Immuno-Oncology: Multiplicity of Drug In-Licensing Opportunities to Expand Your Pipeline

Market Insight:  Ellen S. Baron, PhD, Echoe M. Bouta, PhD

This market update captures assets currently in development and recent partnering/in-licensing transactions which can catalyze development and improve valuation for companies.

Immuno-oncology (IO) has revolutionized the treatment of many deadly cancers in the last seven years. Further, IO continues to shape the pharma industry as the global IO market is expected to more than double over the next eight years to $126.9 billion (GrandView Research). Much of this market growth has been spurred by checkpoint inhibitors with market leader PD-1 antibody Keytruda leading the pack at $7 billion in 2018 revenue. However, only 12.5% of patients respond to checkpoint inhibitors, leaving a large unmet need in the field (Haslam et al. JAMA Netw Open, 2019) and plenty of opportunity to capture market share.

View Full Article